Abstract

Objective

To evaluate the efficacy of autologous hematopoietic stem cell transplantation (auto-HSCT) in patients with favorable-risk acute myeloid leukemia in first remission.

Method

Twenty patients who received auto-HSCT at our center between January 2014 and January 2021 were retrospectively reviewed.

Results

Until last follow-up, three patients in the cohort were dead due to relapse. The estimated 1-year and 5-year overall survival were 95.00% ± 4.87% and 83.82% ± 8.58%, respectively. The estimated 5-year RFS and CIR (cumulative incidence of relapse) were 85.00% ± 7.98% and 15.00% ±7.98%, respectively.

Conclusion

The outcome of auto-HSCT in patients with favorable-risk acute myeloid leukemia in first remission was excellent and auto-HSCT could be an effective treatment for these patients.

Details

Title
Outcome of autologous stem cell transplantation in patients with favorable-risk acute myeloid leukemia in first remission
Author
Chen, Juan; Liu, Li; Ma, Runzhi; Pang, Aiming; Yang, Donglin; Chen, Xin; Wei, Jialin; He, Yi; Zhang, Rongli; Zhai, Weihua; Ma, Qiaoling; Jiang, Erlie; Han, Mingzhe; Zhou, Jiaxi; Feng, Sizhou
Pages
1-6
Section
Research
Publication year
2022
Publication date
2022
Publisher
BioMed Central
e-ISSN
14752867
Source type
Scholarly Journal
Language of publication
English
DOI
https://doi.org/10.1186/s12935-022-02750-4
ProQuest document ID
2737788520
Copyright
© 2022. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.